Association for Accessible Medicines

03/18/2026

Reforming PBM business practices is a regulatory and ethical imperative.

At AAM, we are thankful Congress has recently taken concrete steps to curtail PBM business practices. But MORE needs to be done to realize substantial savings for America's patients.

Prescription medicine pricing and reimbursement processes must be governed by transparency and accountability--and allow for healthy competition. In many cases, this means prioritizing the lower-cost generic & biosimilar medicines that make up 90% of all prescriptions filled in the U.S.

PBMs were established to manage the high costs of prescriptions, but their current opaque practices often dismiss the value of generic & biosimilar medicines, favoring higher-priced brand drugs and increasing costs at the pharmacy counter.

Learn more:https://accessiblemeds.org/wp-content/uploads/2026/02/AAM-Issue-Brief-Reforming-PBMs-to-Unlock-Savings.pdf

03/12/2026

02/25/2026

And that's a wrap! 🎉 Thank you to our AAM event planning team, all attendees, every dedicated sponsor and the speakers, panelists and moderators who truly are the future of generic and biosimilar medicines. YOU are driving what's next for the generic and biosimilar medicines industry—and we are thrilled to see the positive impact we can bring to America's patients when we all work together toward better access to lower-cost prescription medicines. Thanks again for joining us in sunny South Florida! ☀️ Get home safely, everyone!

02/25/2026

A huge thanks to Principal Deputy General Counsel and Chief Counsel for Food, Research, and Drugs, U.S. Department of Health and Human Services, Robert Foster, for an invigorating fireside chat with AAM Board Chair, Bob Hoffman and Maryll Toufanian, member of AAM’s Board Executive Committee and Finance and Audit Committee Officer. The three industry leaders discussed critical policy and advocacy topics impacting generics and biosimilars--and had our attendees on the edge of their seats the entire time!

02/25/2026

Always great to hear from Scott Biggs, Director, Supplier Services, IQVIA. Today, he joined us on the mainstage, where he dove into the dynamics of global and U.S. generic and biosimilar markets and offered insights into biosimilar trends and future patent expirations shaping what's next for our industry. Thank you for your insights and expertise, Scott!

02/25/2026

Huge thank you to Joseph M. Shields, Esq, Chief Executive Officer, Transparency-Rx and Matt Wetzel, JD, Partner, Goodwin Procter LLP for another invigorating panel discussion. Keeping in-line with the "future" theme for , and moderated by AAM's John Murphy III, the discussion offered an overview and implications of the Consolidated Appropriations Act of 2026.

02/25/2026

With around a 90% gap in biosimilar development for biologics losing patent exclusivity over the next decade, the biosimilar void still haunts industry experts — because if nothing changes, impact to America's patients could be devastating. This is why our last panel was so important, as Balaji Prasad, MD of Alvotech, Matt Erick of Biocon Biologics and AAM's Giuseppe Randazzo covered development challenges, and the opportunities available to eliminate U.S. market uptake hurdles and fill the biosimilar void.

Thank you to all our panelists, and please tap here to learn more on the biosimilar void: https://www.iqvia.com/Insights/The-IQVIA-Institute/Reports-and-Publications/Reports/Assessing-the-Biosimilar-Void-in-the-US

02/25/2026

And the Lifetime Achievement Award goes to… Scott Cornwell, CEO, Dispensary of Hope. Congratulations Scott. SO WELL DESERVED! 👏

02/25/2026

With thanks to Keren Haruvi for her dedication and success as former AAM Board Chair, we are now thrilled to welcome Bob Hoffman of Lupin Pharmaceuticals – as our new Chairman of the AAM Board of Directors! Bob most recently served as Vice-Chair with our AAM board, and we are greatly looking forward to all the future holds under his leadership. Congrats to you, Bob!